Kura Oncology to Present at J.P. Morgan Healthcare Conference

Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicines, will participate in the 39th Annual J.P. Morgan Healthcare Conference. CEO Troy Wilson is scheduled to present on January 12, 2021, at 1:30 p.m. PT / 4:30 p.m. ET. The virtual conference takes place from January 11-14, 2021. A live audio webcast of the presentation will be available on Kura's website and an archived replay will be accessible for 30 days post-event. Kura's leading drug candidates include tipifarnib and KO-539, targeting key cancer pathways.

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 39^th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, January 12, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The virtual conference will be held from January 11-14, 2021.

A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com 

FAQ

When is Kura Oncology's presentation at the J.P. Morgan Healthcare Conference?

Kura Oncology's presentation is scheduled for January 12, 2021, at 1:30 p.m. PT / 4:30 p.m. ET.

What is the focus of Kura Oncology's presentation?

Kura Oncology will provide an overview of its operations and drug development efforts.

How can I access the Kura Oncology presentation?

The presentation will be available via live audio webcast on Kura's website, with a replay accessible for 30 days.

What drugs are highlighted in Kura Oncology's pipeline?

Kura's pipeline includes tipifarnib, which is in a registration-directed trial, and KO-539, currently in Phase 1/2A clinical trials.

What event is Kura Oncology participating in?

Kura Oncology is participating in the 39th Annual J.P. Morgan Healthcare Conference.